Former Head of Boehringer Ingelheim Animal Health, Dr. Joachim Hasenmaier, Joins Invetx Board of Directors
BOSTON, Mass. – January 6, 2021 – Invetx, a pioneer in protein-based therapeutics for animal health, announced today that Dr. Joachim Hasenmaier has joined the company’s board of directors.
Dr. Hasenmaier was most recently a member of the board of managing directors of Boehringer Ingelheim, a world-leading, research-driven pharmaceutical company, where he oversaw the animal health and consumer health care businesses. Previously, as head of animal health of Boehringer Ingelheim, he led the rapid growth and expansion of the business, including the acquisition of a significant part of the Fort Dodge Animal Health product portfolio as well as the successful acquisition and integration of the Sanofi/Merial animal health units. Dr. Hasenmaier received his doctor of veterinary medicine (Dr.med.vet.) degree from the University of Munich and his MBA from the Kellogg School of Management at Northwestern University.
“Invetx is very pleased to welcome Dr. Hasenmaier, a well-respected leader and highly successful business strategist in the animal health industry, to its board,” said Juergen Horn, PhD, chief executive officer, Invetx. “Dr. Hasenmaier’s commercial and industry expertise will be extremely valuable as we rapidly advance our portfolio of innovative antibody therapeutics towards the market.”
“There is no doubt that biotherapeutics will play an increasingly important role in veterinary medicine and be a key driver of growth for the animal health industry,” said Dr. Hasenmaier. “I have been very impressed with the integrated discovery and development platform that the Invetx team has created and the value potential of the company’s pipeline. I am looking forward to working with the Invetx team and colleagues on the board of directors.”
Invetx’s unique platform capabilities set a new standard for veterinary monoclonal antibodies and extend across a wide range of indications and targets. Targeted biotherapeutics account for a significant number of approved drugs in humans and many of these targets and indications are also relevant in veterinary medicine. Invetx is initially focused on chronic and serious diseases in dogs and cats but is planning to expand its technology platform and pipeline into new areas.
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine.
The company completed a $25.5 million Series A financing in 2020 with investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment partners are AbCellera Biologics, a biotech company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts. For more information, see www.invetx.com.
Partners and investors:
Juergen Horn, PhD
Chief Executive Officer